In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole

December 2019 in “ Pharmaceutics ”

Seong-Wook Seo, Jin Woo Park, Dong-Gyun Han, Jimin Kim, Sang-Hyun Kim, Taeuk Park, Kyung‐Hwa Kang, Min Yang, In‐Soo Yoon

Dutasteride Ketoconazole 6β-hydroxydutasteride azole antifungal drugs high-performance liquid chromatography fluorescence detection pharmacokinetics metabolism H-DUT HPLC-FL

From the encyclopedia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Ketoconazole →

antifungal with some anti-androgenic benefits, often used as a shampoo

Studysummary This study found that co-administration of ketoconazole significantly altered the pharmacokinetics of dutasteride in rats, suggesting an interaction potential between dutasteride and azole antifungal drugs. Our plain-language summary of this paper — not a Tressless recommendation.

In 2019, a study was conducted to investigate the potential interaction between Dutasteride, a drug used for treating hair loss, and Ketoconazole, an antifungal medication. The research was conducted both in vitro and in vivo. The results showed that co-administration of Dutasteride and Ketoconazole led to a significant increase in the systemic exposure of Dutasteride, suggesting that Ketoconazole inhibits the metabolism of Dutasteride, which could potentially lead to increased side effects. The study also developed a high-performance liquid chromatography with fluorescence detection (HPLC-FL) method for simultaneous determination of Dutasteride and its major active metabolite, 6β-hydroxydutasteride (H-DUT). The pharmacokinetics of Dutasteride and H-DUT were significantly altered by the co-administration of Ketoconazole. This was the first study to show the drug interaction potential of Dutasteride with azole antifungal drugs including Ketoconazole.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Dutasteride in Androgenetic Alopecia: An Update

27 citations , March 2017 in “Current Clinical Pharmacology”

In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.

research Design of a Gelatin Microparticle-Containing Self-Microemulsifying Formulation for Enhanced Oral Bioavailability of Dutasteride

16 citations , June 2015 in “Drug Design Development and Therapy”

This study found that a gelatin microparticle-containing self-microemulsifying formulation combined with Soluplus improved the oral absorption of dutasteride.

research Antipsychotic-Like Properties of 5-Alpha-Reductase Inhibitors

64 citations , March 2008 in “Neuropsychopharmacology”

research Dutasteride

45 citations , January 2008 in “Drugs”

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor

58 citations , March 2006 in “Current topics in medicinal chemistry”

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

research Dutasteride: A Review of Current Data on a Novel Dual Inhibitor of 5-Alpha Reductase

38 citations , January 2005 in “PubMed”

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

research Dihydrotestosterone And The Prostate: The Scientific Rationale For 5α-Reductase Inhibitors In The Treatment Of Benign Prostatic Hyperplasia

235 citations , September 2004 in “The Journal of urology/The journal of urology”

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

research 5alpha-Reductase: History and Clinical Importance

62 citations , January 2004 in “PubMed”

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

research Androgens and Alopecia

165 citations , December 2002 in “Molecular and Cellular Endocrinology”

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.